SAN FRANCISCO and WALTHAM, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing differentiated biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD) and other inflammatory and immunology (I&I) indications, today announced that Michael Henderson, M.D., Chief Executive Officer of Apogee, will present at the 42nd Annual J.P. Morgan Conference on Tuesday, January 9, 2024 at 7:30 a.m. P.T. / 10:30 a.m. E.T.
A live and archived webcast of the presentation will be available via the News & Events page in the Investors section of the Apogee Therapeutics website.
About Apogee Therapeutics
Apogee Therapeutics is a clinical-stage biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD) and other inflammatory and immunology indications with high unmet need. Apogee’s antibody programs are designed to overcome limitations of existing therapies by targeting well-established mechanisms of action and incorporating advanced antibody engineering properties, including half-life extension. The company’s two most advanced programs are APG777 and APG808, which are being initially developed for the treatment of AD and COPD, respectively. Based on a broad pipeline and depth of expertise, the company believes it can deliver value and meaningful benefit to patients underserved by today’s standard of care. For more information, please visit www.apogeetherapeutics.com.
Investor Contacts:
Noel Kurdi
VP of Investor Relations
Apogee Therapeutics
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contact:
Dan Budwick 1AB Media
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$53.97 |
| Daily Change: | -0.38 -0.70 |
| Daily Volume: | 165,820 |
| Market Cap: | US$2.920B |
October 08, 2025 August 11, 2025 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
